OTC · NVTAQ
Healthcare · Medical - Diagnostics & Research
$0.00
Down-$0.00 (-25.00%)
Updated Aug 23, 2026, 7:58 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NVTAQ does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NVTAQ.
NVTAQ research
Company profile and research snapshot.
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Zacks Investment Research · May 13, 2024
Olink Holding (OLK) delivered earnings and revenue surprises of -8.33% and 8.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVTAQ.
No results
No recent SID articles mention NVTAQ.
